Companies 0 See All

Hedge Funds 0 See All

Insiders 0 See All

Institutional Investors 0 See All

Click here to see all results for

Home > Insider Trading > Filing (0001209191-19-018817)

Filing Details

Accession Number:: 0001209191-19-018817
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2019-03-12 16:38:50
Reporting Period:: 2019-03-06

Accepted Time:: 2019-03-12 16:38:50
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1652130	Intellia Therapeutics Inc.	NTLA	In Vitro & In Vivo Diagnostic Substances (2835)	364785571

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1738456	Andrew Schiermeier	C/O Intellia Therapeutics, Inc. 40 Erie Street, Suite 130 Cambridge MA 02139	Evp, Dev And Corp Strategy	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2019-03-06	3,250	$16.00	3,250	No	4	P	Direct
Common Stock	Acquisiton	2019-03-06	4,250	$15.50	7,500	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct
No	4	P	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	8,644	Direct

Footnotes

Includes 1,091 and 53 shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on June 30, 2018 and December 31, 2018, respectively.